Provepharm is an affiliated company of the privately-held Provence Technologies Group, devoted to : • Develop and market drugs made from pharmaceutical active substances (or API) synthesized and patented by its parent company, and • Licence and market such API to third parties, for human health applications. Provepharm’s expertise is stemming from experienced managers coming from the international pharmaceutical & medical device industries and enthusiastic project managers focusing on rewarding results. The team thinks and acts differently in a streamlined organisation with fast decision-making; skills are geared to manage agile processes involving outsourced operations at CROs and CMOs with world-class recognition. Provepharm recognized the pharmaceutical industry interest to explore known API in new indications and the need for such compounds at quality levels matching ever-increasing technical and regulatory requirements in a changing global world. Methylene Blue is the first compound which went through such a complete and innovative revamping, from active substance clean chemical synthesis to pharmaceutical R&D and European regulatory recognition in less than three years.